IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine

2 years ago

Board strengthened with appointments of Tim Haines (Abingworth) as Non-executive Chair and Dr Oliver Nussbaumer (co-founder of GammaDelta Therapeutics and…

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders

2 years ago

         PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted…

Sirona Biochem Corporate Update January 2024

2 years ago

VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides…

Everest Group recognizes Indegene as a Leader in Life Sciences Digital Services Specialist PEAK Matrix® Assessment 2024

2 years ago

Everest Group recognizes Indegene as a Leader in Life Sciences Digital Services Specialist PEAK Matrix® Assessment 2024 Everest Group recognizes…

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

2 years ago

SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with…

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

2 years ago

SAN MATEO, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing…

Vision Sensing Acquisition Corp. Received Nasdaq Delisting Determination Letter and Intends to Appeal the Determination and Request a Stay Pending the Appeal Hearing

2 years ago

NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company” or “VSAC”),…

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

2 years ago

BURLINGAME, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to…

STERIS to Host a Conference Call for Fiscal 2024 Third Quarter Financial Results on February 8, 2024

2 years ago

DUBLIN, IRELAND, Jan. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it…

Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital

2 years ago

Refinancing replaces prior senior credit facilityMENLO PARK, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight…